Effect of Guanxin Danshen Dripping Pills on Coronary Heart Disease Comorbid with Depression or Anxiety: The ADECODE-Real World Study

Objective To evaluate the efficacy of Guanxin Danshen Dripping Pill (GXDSDP) in treating anxiety and depression in patients with coronary heart disease (CHD). Methods A total of 1,428 patients diagnosed with CHD screened for anxiety, depression, and quality of life (QOL) at baseline received 0.4 g o...

Full description

Saved in:
Bibliographic Details
Published in:Chinese journal of integrative medicine 2024-05, Vol.30 (5), p.443-448
Main Authors: Wu, Shi-hao, Shi, Wei-qi, Li, Yu-hang, Liu, Ru-hui, Hu, Da-yi, Zheng, Li-qiang, Ma, Wen-lin
Format: Article
Language:English
Subjects:
Aged
Anxiety - complications
Anxiety - drug therapy
Camphanes
Clinical Experience
Comorbidity
Coronary Disease - complications
Coronary Disease - drug therapy
Coronary Disease - epidemiology
Depression - complications
Depression - drug therapy
Drugs, Chinese Herbal - therapeutic use
Female
Humans
Male
Medicine
Medicine & Public Health
Middle Aged
Panax notoginseng
Quality of Life
Salvia miltiorrhiza
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To evaluate the efficacy of Guanxin Danshen Dripping Pill (GXDSDP) in treating anxiety and depression in patients with coronary heart disease (CHD). Methods A total of 1,428 patients diagnosed with CHD screened for anxiety, depression, and quality of life (QOL) at baseline received 0.4 g of GXDSDP treatment 3 times per day and returned for monthly reassessment. Patients were recruited after stable treatment for CHD and received assessment of General Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-9 (PHQ-9), and Seattle Angina Questionnaire (SAQ) for evaluating anxiety, depression, and QOL. Patients were followed up 3 times, once every 4 weeks, during outpatient visits for 12 weeks. Results At the third follow-up (F3), the anxiety symptom of 63.79% (673/1,055) of the patients improved to sub-clinical level, and the GAD-7 score improved significantly (8.11 vs. 3.87, P
ISSN:1672-0415
1993-0402
DOI:10.1007/s11655-023-3628-x